ReviewCureus2025
Diabetes Mellitus and Cognitive Decline: A Systematic Review Exploring the Link to Dementia and Neurodegenerative Diseases.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence, risk factors, and early prediction of cognitive impairment in patients with diabetes mellitus: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Association Between Serum Adropin Levels and Cognitive Impairment in the Elderly: A Cross-Sectional Study.Clinical neuropsychiatry · 2026Article
- Atrial Fibrillation and Cognitive Decline: Mechanisms, Evidence, and Preventive Strategies-A Narrative Review.Journal of clinical medicine · 2026Review
- Altered static and dynamic functional network connectivity between subcortical nuclei and cortical regions of the default mode network in type 2 diabetes mellitus.Frontiers in neuroscience · 2026Article
- Prions and protein aggregates as pathogens, self-propagating structures, biomarkers, and therapeutic targets.Microbiology and molecular biology reviews : MMBR · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This systematic review explores the association between diabetes mellitus (DM) and cognitive decline, with a particular focus on neurodegenerative diseases such as dementia and Alzheimer's disease (AD). A comprehensive search strategy, conducted in accordance with Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines, identified and selected nine meta-analyses of high relevance and methodological rigor. These studies encompassed diverse populations, including stroke survivors, apolipoprotein E (APOE) ɛ4 carriers, and individuals with metabolic syndrome, and examined both interventions, such as glucose-lowering therapies, and risk factors, including hypoglycemia and poor glycemic control. Key findings indicate that diabetes is a significant risk factor for cognitive decline, with strong associations observed between impaired glucose metabolism and elevated tau biomarkers. Glucose-lowering therapies, particularly sodium-glucose cotransporter-2 (SGLT-2) inhibitors and metformin, demonstrated potential neuroprotective effects, reducing the risk of dementia and cognitive impairment. However, heterogeneity among the studies and variability in study designs highlight the need for further high-quality research to validate these findings and elucidate underlying mechanisms. This review underscores the importance of integrating cognitive health into diabetes management and highlights the potential of targeted interventions to mitigate the cognitive burden associated with diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.